Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
52-week open-label extension of pimavanserin in children and adolescents with irritability associated with autism spectrum disorder
2021-005388-32Phase 2Active
- Sponsor
- Acadia Pharmaceuticals
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pimavanserin in Autism Spectrum Disorder (ASD), sponsored by Acadia Pharmaceuticals. Primary endpoint: Treatment-emergent adverse events. Started May 2022; status: active.
02
Drugs
pimavanserin
03
Conditions
Autism Spectrum Disorder (ASD)
Beyond the preview
Go deeper on 2021-005388-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005388-32.